15 Most Promising Mid-Cap Healthcare Stocks Under $50

Page 12 of 15

4. Dyne Therapeutics (NASDAQ:DYN)

Sector/Industry: Healthcare (Biotechnology)

Share Price: $19.85

Potential Upside: 93.5%

Number of Hedge Fund Holders: 45

Dyne Therapeutics (NASDAQ:DYN) is one of the most promising mid-cap healthcare stocks under $50.

As of the December 19 closing, the consensus analyst sentiment towards Dyne Therapeutics (NASDAQ:DYN) remains bullish. After a decline of almost 16% during 2025, the stock has received coverage from 10 analysts. 80% of them assigned Buy ratings, and the remaining 20% gave Hold calls. Such bullish forecasts have led to an estimated 1-year average price target of $38.40 per share, implying more than 93% upside for investors.

On December 15, Evercore ISI analyst Gavin Clark-Gartner reaffirmed his bullish stance on Dyne Therapeutics (NASDAQ:DYN). He assigned a Buy rating to the stock with a target price of $36. This implies a substantial upside potential of more than 81% for investors, compared with the stock’s current trading level.

Clark-Gartner’s Buy rating on Dyne Therapeutics (NASDAQ:DYN) stock is based on the company’s encouraging trends in functionality. He also highlighted how certain metrics on efficacy and safety remain in line with expectations. He sees these factors as a favorable catalyst for the stock after the company recently carried out a fundraising round.

Dyne Therapeutics (NASDAQ:DYN) is a biotechnology company that formulates life-transforming targeted therapeutics for individuals with genetically driven neuromuscular diseases. Dyne Therapeutics (NASDAQ:DYN) makes use of its FORCE platform to identify the root cause of a condition, and currently has a strong pipeline of clinical and preclinical programs.

Page 12 of 15